Multiple Sclerosis Research Today is a free monthly online journal that collates and summarizes the latest research about Multiple Sclerosis, including details on diagnosis, symptoms, treatment, prognosis.

Volume 6 (2009), Issue 1 (January)

1. Neutralizing and binding antibodies to interferon beta in patients with multiple sclerosis: a comparison of assay results from three italian centres.
   J Immunoassay Immunochem, 30(1): 40-50. [Abstract] [Full-text]
2. IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production.
   PLoS Genet, 5(1): e1000322. [Abstract] [Full-text]
3. Design and synthesis of a cyclic double mutant peptide (cyclo(87-99)[A91,A96]MBP87-99) induces altered responses in mice after conjugation to mannan: implications in the immunotherapy of multiple sclerosis.
   J Med Chem, 52(1): 214-8. [Abstract] [Full-text]
4. Oligoclonal myelin-reactive T-cell infiltrates derived from multiple sclerosis lesions are enriched in Th17 cells.
   Clin Immunol, 130(2): 133-44. [Abstract] [Full-text]
5. Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis.
   Clin Immunol, 130(2): 145-50. [Abstract] [Full-text]
6. Genomic NGFB variation and multiple sclerosis in a case control study.
   BMC Med Genet, 9: 107. [Abstract] [Full-text]
7. IL2RA/CD25 gene polymorphisms: uneven association with multiple sclerosis (MS) and type 1 diabetes (T1D).
   PLoS ONE, 4(1): e4137. [Abstract] [Full-text]
8. Chronic myeloid leukaemia in two multiple sclerosis patients on interferon beta-1a.
   J Clin Pharm Ther, 34(1): 125-7. [Abstract] [Full-text]
9. Complement in multiple sclerosis: its role in disease and potential as a biomarker.
   Clin Exp Immunol, 155(2): 128-39. [Abstract] [Full-text]
10. Comorbidity delays diagnosis and increases disability at diagnosis in MS.
    Neurology, 72(2): 117-24. [Abstract] [Full-text]
11. Association of the HLA-DPB1*0501 allele with anti-aquaporin-4 antibody positivity in Japanese patients with idiopathic central nervous system demyelinating disorders.
    Tissue Antigens, 73(2): 171-6. [Abstract] [Full-text]
12. The effects of blood-brain barrier disruption on glial cell function in multiple sclerosis.
    Biochem Soc Trans, 37: 329-31. [Abstract] [Full-text]
13. Multiple sclerosis relapses: a multivariable analysis of residual disability determinants.
    Acta Neurol Scand, 119(2): 126-30. [Abstract] [Full-text]
14. Regional DTI differences in multiple sclerosis patients.
    Neuroimage, 44(4): 1397-403. [Abstract] [Full-text]
15. Azathioprine for multiple sclerosis.
    J Neurol Neurosurg Psychiatry, 80(2): 131-2; discussion 132. [Abstract] [Full-text]
16. Regional variations in the extent and pattern of grey matter demyelination in multiple sclerosis: a comparison between the cerebral cortex, cerebellar cortex, deep grey matter nuclei and the spinal cord.
    J Neurol Neurosurg Psychiatry, 80(2): 182-7. [Abstract] [Full-text]
17. Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy.
    J Neurol Neurosurg Psychiatry, 80(2): 201-6. [Abstract] [Full-text]
18. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis.
    Hum Mol Genet, 18(4): 767-78. [Abstract] [Full-text]
19. The prevalence of overweight and obesity in veterans with multiple sclerosis.
    Am J Phys Med Rehabil, 88(2): 83-91. [Abstract] [Full-text]
20. Attentional lapses, emotional regulation and quality of life in multiple sclerosis.
    Br J Clin Psychol, 48: 101-6. [Abstract] [Full-text]

© 2004-2012 Multiple Sclerosis Research Today. All Rights Reserved.